Skip to Content
Biopharmaceutical company AbbVie had a strong year, with revenues growing nearly 23%. Sales for the company’s top-performing immune defense drugs continued to rise in 2021, especially domestically, where revenues for the best-selling Humira drug increased by 7.6%. Humira did not perform as well on the global market, where it was edged out by biosimilar competition, but international revenues for products including plaque psoriasis treatment Skyrizi and rheumatoid arthritis drug Rinvoq rose by several billion dollars each. AbbVie predicted strong growth in 2022 with an increased focus on expanding its products’ coverage in both American and European markets.
Smith Collection—Getty Images
Lists ranking AbbVie
World’s 25 Best Workplaces - 2022Organizations on this annual list positively impac...READ MOREview in list
10 Best Large Workplaces in Biotechnology and Pharmaceuticals - 2022See which workplaces made this year's list....READ MOREview in list
Global 500 - 2022Aggregate sales hit $37.8 trillion last year—an in...READ MOREview in list
15 Best Large Workplaces in Chicago - 2022Winning workplaces in Chicagoland earned high mark...READ MOREview in list
Fortune 500 - 2022This year’s Fortune 500 marks the 68th running of ...READ MOREview in list
Fortune 100 Best Companies to Work For - 2022When it comes to supporting employees, flexibility...READ MOREview in list
World’s Most Admired Companies - 2021After a year in which humanity leaned more heavily...READ MOREview in list